AAN 2016: Implementing Disease Modifying Therapies in the Management of Patients with Multiple Sclerosis
This CME program will focus on information presented at the 68th Annual American Academy of Neurology Meeting held in Vancouver, Canada on April 15-21, 2016. The latest advances in treatment options and methods of slowing disease progression will be discussed by three expert faculty. Recent clinical trial data, including that pertaining to disease monitoring therapies, will be reviewed and related to practice. Methods of creating patient-specific treatment plans utilizing existing data and resources will also be relayed to the learner. This program will allow physicians to better acquaint themselves with the ever evolving science of the field, in order to more accurately manage their patients with multiple sclerosis and, ultimately, improve patient outcomes.
This activity has been designed to meet the educational needs of neurologists and other healthcare professionals responsible for the treatment of patients with MS.
Upon completion of this activity, participants will be able to:
- Review the science of multiple sclerosis and slowing disease progression.
- Examine clinical trial data of disease monitoring therapies for the treatment of multiple sclerosis.
- Develop data-driven treatment plans to effectively address patient-specific characteristics and improve outcomes for patients with multiple sclerosis.
Fred D. Lublin, MD
Andrew D. Goodman, MD
Clyde Markowitz, MD
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Faculty||Relationship Identified With:|
|Fred D. Lublin, MD|
Consultant/Advisor: AbbVie Inc.; Acorda Therapeutics Inc.; Actelion Pharmaceuticals US, Inc.; Akros Pharma Inc.; Amgen Inc.; Atara Biotherapeutics; Bayer AG; Biogen; EMD Serono, Inc.; Genentech, Inc.; Genzyme Corporation; Forward Pharma A/S; Mallinckrodt; MedDay; MedImmune; Novartis AG; Osmotica Pharmaceutical Corp.; Teva Pharmaceutical Industries Ltd.; TG Therapeutics, Inc.; Toyama Pharmaceutical Co. Ltd; XenoPort, Inc.
Grant/Research Support: Biogen; Genzyme Corporation; Celgene Corporation; National Institutes of Health; National Multiple Sclerosis Society; Novartis AG; Teva Pharmaceutical Industries Ltd.; Transparency Life Sciences
Speaker's Bureau: Genentech, Inc.; Genzyme Corporation
Stock Ownership: Cognition Pharmaceuticals, Inc.
Andrew Goodman, MD
Consultant/Advisor: AbbVie Inc.; Acorda Therapeutics Inc.; Atara Biotherapeutics; Bayer AG; Biogen IDEC; EMD Serono, Inc.; Genzyme Corporation, a Sanofi company; Novartis Pharmaceuticals Corporation; Teva Pharmaceutical Industries Ltd.
Grant/Research Support: Acorda Therapeutics Inc.; Avanir Pharmaceuticals, Inc.; Biogen; EMD Serono, Inc.; Genzyme Corporation; Novartis AG; ONO PHARMACEUTICAL CO., LTD.; F. Hoffmann-La Roche Ltd; Sun Pharmaceutical Industries Ltd.; Teva Pharmaceutical Industries Ltd.
Clyde Markowitz, MD
Consultant/Advisor: Bayer AG; Biogen; EMD Serono, Inc.; Genentech, Inc.; Genzyme Corporation; Novartis AG; Opexa Therapeutics, Inc.; F. Hoffmann-La Roche Ltd; Teva Pharmaceutical Industries Ltd.
Non-faculty: Sandy Breslow; Alison Kemp; Leah Johnson; Timothy Hayes, MD, PhD; Kristin Scollon; Emma Gilmartin; Nicole Brestowski; and Bernard M. Abrams, MD hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercials interest related to the content of this activity of any amount during the past 12 months.
This CME activity has been supported by an independent educational grant from Novartis Pharmaceuticals Corporation.
Co-provided by the Elsevier Office of Continuing Medical Education and AcademicCME.
CME Credit (Physicians)
The Elsevier Office of Continuing Medical Education is accredited by the Acceditation Council for Continuing Medical Education (ACCME) to provide continuing education for physicians.
The Elsevier Office of Continuing Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credit™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at firstname.lastname@example.org. Additional information on the process of converting AMA PRA Category 1 Credits™ to ECMECs® can be found at: www.eaccme.eu.
CME INQUIRIES/SPECIAL NEEDS
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Elsevier Office of Continuing Medical Education, AcademicCME and Novartis Pharmaceuticals Corporation do not recommend the use of any agent outside of the labeled indications.
Disclaimer Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
- 1.00 AMA PRA Category 1 Credit(s)™
- 1.00 Non-physician